Partner Headlines - MDVN

  1. Valeant Agrees To Buy Dendreon's Provenge

    IBD
  2. Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation ...

    GuruFocus
  3. Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically ...

    GuruFocus
  4. J&J Earnings Beat, But Sales, Guidance Miss Estimates

    IBD
  5. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  6. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  7. Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

    Benzinga
  8. William Blair's Top BioPharmaceutical Stock Picks for Q1 2015

    GuruFocus
  9. Newly Profitable Medivation Riding High On Drug Sales

    IBD
  10. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD
  11. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga
  12. Medivation Hits High After Q3 Earnings Beat

    IBD
  13. Medivation Hits High After Q3 Earnings Beat

    IBD
  14. Medivation and Astellas Announce Phase 3 Study of Enzalutamide ...

    GuruFocus
  15. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  16. Consider Medivation for Your Portfolio

    FoxBusiness
  17. Benzinga's Top Downgrades

    Benzinga
  18. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  19. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  20. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  21. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  22. Stifel Raises Medivation Inc Price Target

    Benzinga
  23. Stocks Hitting 52-Week Highs

    Benzinga
  24. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  25. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  26. Benzinga's Volume Movers

    Benzinga
  27. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  28. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  29. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  30. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  31. Benzinga's Top Upgrades

    Benzinga
  32. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  33. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  34. Morning Market Movers

    Benzinga
  35. Stocks To Watch For April 1, 2014

    Benzinga
  36. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  37. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  38. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  39. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  40. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  41. Benzinga's Top #PreMarket Losers

    Benzinga
  42. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  43. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  44. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  45. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  46. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  47. Stocks Hitting 52-Week Highs

    Benzinga
  48. Benzinga's Top #PreMarket Gainers

    Benzinga
  49. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  50. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  51. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  52. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  53. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  54. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  55. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  56. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  57. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  58. Benzinga's Top Initiations

    Benzinga
  59. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  60. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  61. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  62. Medivation Effects 2-for-1 Stock Split

    Benzinga
  63. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  64. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  65. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  66. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  67. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  68. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  69. Stocks Hitting 52-Week Highs

    Benzinga
  70. Health Care Sector Wrap

    FoxBusiness
  71. Four Winning Trades Based on Analyst Calls

    Benzinga
  72. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  73. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  74. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  75. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  76. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  77. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  78. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  79. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  80. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  81. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  82. Will Johnson & Johnson Cure Cancer?

    Benzinga
  83. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  84. Notable Put Options Activity in Medivation

    Benzinga
  85. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  86. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  87. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  88. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  89. Jefferies Raises PT on Medivation to $95

    Benzinga
  90. Wedbush Raises PT on Medivation to $81

    Benzinga
  91. Medivation and Astellas Announce Positive Results From the Phase ...

    Benzinga
  92. Upgrades & Downgrades: AZO, MDVN, POT, TSLA, and UA

    SchaeffersResearch
  93. Gilead, Celgene Join Big Pharma On M&A Front

    IBD
  94. Alzheimer's drug test halted

    IBD
  95. Best Biotech Stocks of 2011

    Benzinga
  96. Options Players Get Bearish with Medivation Puts

    SchaeffersResearch
  97. Notable Put Options Activity in Medivation

    Benzinga
  98. Put Volume Heats Up as Medivation Surges to a New High

    SchaeffersResearch
Trading Center